Basel, Switzerland
Basel, Switzerland

Time filter

Source Type

News Article | February 21, 2017
Site: globenewswire.com

Dublin, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Therapeutic Drug Monitoring - Technologies, Markets, and Companies" to their offering. This report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcome. TDM is viewed as a component of personalized medicine that interacts with several other disciplines including pharmacokinetics and pharmacogenetics. One chapter is devoted to monitoring of drugs of abuse (DoA). Various technologies used for well-known DoA are described. A section on drug abuse describes methods of detection of performance-enhancing drugs. TDM market is analyzed from 2015 to 2025 according to technologies as well as geographical distribution. Global market for DoA testing was also analyzed from 2016 to 2026 and divided according to the area of application. Unmet needs and strategies for development of markets for TDM are discussed. The report contains profiles of 27 companies involved in developing tests and equipment for drug monitoring along with their collaborations. The text is supplemented with 18 tables, 6 figures and 190 selected references from literature. Benefits of this report: - Up-to-date one-stop information on therapeutic drug monitoring - Description of 27 companies involved with their collaborations in this area - Market analysis 2016-2026/ - Market values in major regions - Strategies for developing markets for therapeutic drug monitoring - A selected bibliography of 190 publications - Text is supplemented by 18 tables and 6 figures Who should read this report? - Biotechnology companies developing assays and equipment for drug monitoring - Reference laboratories providing drug monitoring services - Pharmaceutical companies interested in companion tests for monitoring their drugs - Clinical pharmacologists interested in integrating therapeutic drug monitoring with pharmacogenetics for development of personalized medicine Key Topics Covered: Executive Summary 1. Introduction Definitions Historical Landmarks in the development of TDM Pharmacology relevant to TDM Pharmacokinetics Pharmacodynamics Pharmacogenetics Pharmacogenomics Pharmacoproteomics Drug receptors Protein binding Therapeutic range of a drug Variables that affect TDM Indications for TDM Multidisciplinary nature of TDM 2. Technologies for TDM Introduction Sample preparation Proteomic technologies Mass spectrometry Liquid chromatography MS Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Combining capillary electrophoresis with MS Gas-liquid chromatography Tissue imaging mass spectrometry New trends in sample preparation Pressure Cycling Technology Desorption electrospray ionization imaging High Performance Liquid Chromatography (HPLC) Ultra performance LC TDM using dry blood spots Analysis of dried blood spots for drugs using DESI Quantitative analysis of drugs in dried blood spot by paper spray MS Immunoassays Enzyme-linked immunosorbent assay Cloned Enzyme Donor Immunoassay Enzyme Multiplied Immunoassay Technique Fluorescence Polarization Immunoassay Particle Enhanced Turbidimetric Inhibition Immunoassay Radioimmunometric assays Biosensors Nanosensors Biochips & Microarrays Introduction Microchip capillary electrophoresis Phototransistor biochip biosensor Microchip-based fluorescence polarization immunoassay for TDM Cellular microarrays Microfluidics for TDM Lab-on-a-chip Micronics' microfluidic technology Rheonix CARD technology Nano-interface in a microfluidic chip Levitation of nanofluidic drops with physical forces Nanoarrays Nanobiotechology NanoDx Biomarkers Applications of biomarkers in drug safety studies Genomic technologies for toxicology biomarkers Proteomic technologies for toxicology biomarkers Metabonomic technologies for toxicology biomarkers Integration of genomic and metabonomic data to develop toxicity biomarkers Toxicology studies based on biomarkers Biomarkers of hepatotoxicity Biomarkers of nephrotoxicity Cardiotoxicity Neurotoxicity Biomarkers in clinical trials Molecular diagnostics 3. Drug Monitoring Instruments Introduction Description of important instruments AB SCIEX instruments AB SCIEX LC/MS/MS Abbott instruments ARCHITECT c16000 ARCHITECT c4000 ARCHITECT c8000 ARCHITECT ci16200 Integrated System ARCHITECT ci4100 Integrated System ARCHITECT ci8200 integrated with the ARCHITECT i2000SR ARCHITECT i1000SR ARCHITECT i4000SR AxSYM Agilent's 6400 Series Triple Quadrupole LC/MS Alfa Wassermann's ACE Alera AMS Diagnostics' LIASYS Awareness Technology's STAT FAX 4500 Beckman Coulter instruments Beckman Coulter Unicel Series AU5800 automated chemistry systems AU480 Binding Site ESP600 bioMerieux Mini Vidas Carolina BioLis 24i Chromsystems' HPLC instruments Grifols Triturus ABX Pentra 400 Medica EasyRA Nova Biomedical Critical Care Xpress Ortho Clinical Diagnostics' VITROS® family of systems Immunodiagnostic systems Randox intruments Randox RX Imola Roche instruments Cobas® 8000 COBAS INTEGRA® Systems Siemens instruments ADVIA 1200 ADVIA Centaur XP immunoassay system EMIT® II Plus Syva® Viva® Drug Testing Systems Dimension® Xpand® Plus Integrated Chemistry System Thermo Scientific instruments Indiko Tosoh AIA-Series 4. Applications of TDM Introduction Pharmaceutical research and drug development Clinical trials Computerized clinical decision support systems for TDM and dosing Medication-related interferences with measurements of catecholamines Polymorphisms of genes affecting drug metabolism TDM for drug safety TDM in special groups The aged Children Pregnancy TDM of prophylactic therapy Monitoring of vitamin D levels Monitoring of RBC folic acid levels during pregancy Personalized medicine Role of TDM in personalized medicine Applications according to various conditions Anesthesia and critical care Optimizing antimicrobial dosing for critically ill patients TDM monitoring of thiopental continuous infusion in critical care Role of TDM in critical care cardiac patients. Cancer Epilepsy Personalized approach to use of AEDs Infections Virus infections Fungal infections Pain management Role of TDM in pain management Monitoring of analgesic drugs in urine samples AEDs as analgesics Triptans for migraine Psychiatric disorders Guidelines for use of TDM in psychiatric patients TDM of psychotropic drugs Transplantation TDM of Tacrolismus in transplantation TDM of cyclosporine A in transplantation Monitoring of immunosuppression with mycophenolate mofetil Emergency toxicology Future prospects of TDM 5. Drugs Requiring Monitoring Introduction Antiepileptics Carbamazepine TDM of carbamazepine Gabapentin Lacosamide Lamotrigine TDM of lamotrigine Levetiracetam TDM of levetiracetam Phenobarbital TDM of phenobarbital Phenytoin TDM of phenytoin Primidone TDM of primidone Topiramate TDM of topiramate Valproic acid TDM of valproic acid TDM of multiple antiepileptic drugs in plasma/serum Antimicrobials Antibiotics Amikacin Anti-tuberculosis drugs Chloramphenicol Gentamicin Tobramycin Vancomycin Norvancomycin Antiviral agents Anti-HIV drugs Antifungal agents Voriconazole Antidepressants TDM of selective serotonin reuptake inhibitors Antipsychotics Aripiprazole Quetiapine TDM of risperidone TDM of AEDs in psychiatric disorders TDM of multiple drugs in psychiatry Bronchodilators Theophylline Cardiovascular drugs Antiarrhythmic drugs Anticoagulants Dabigatran Antihypertensive drugs ß-blockers Cardiotonic drugs Digoxin TDM of statins for hypercholesterolemia Chemotherapy for cancer TDM of 5-FU TDM of Methotrexate TDM of imitanib Drugs used for treatment of Alzheimer disease Donepezil Galantamine Memantine Drugs used for treatment of Parkinson disease Monitoring of levodopa and carbidopa therapy Catechol-O-methyltransferase inhibitors Drugs for treatment of attention-deficit hyperactivity disorder Atomoxetine Methylphenidate Hypnotic-sedative drugs Benzodiazepines Propofol Immunosuppressive drugs TDM of mycophenolic acid for the treatment of lupus nephritis Steroids Prednisone Miscellaneous drugs Azathioprine Sildenafil 6. Monitoring of Biological Therapies Introduction Cell therapy In vivo tracking of cells Molecular imaging for tracking cells MRI technologies for tracking cells Superparamagnetic iron oxide nanoparticles as MRI contrast agents Visualization of gene expression in vivo by MRI Gene therapy Application of molecular diagnostic methods in gene therapy Use of PCR to study biodistribution of gene therapy vector PCR for verification of the transcription of DNA In situ PCR for direct quantification of gene transfer into cells Detection of retroviruses by reverse transcriptase (RT)-PCR Confirmation of viral vector integration Monitoring of gene expression Monitoring of gene expression by green fluorescent protein Monitoring in vivo gene expression by molecular imaging Monoclonal antibodies Natalizumab 7. Monitoring of Drug Abuse Introduction Tests used for detection of drug abuse Forensic applications of detection of illicit drugs in fingerprints by MALDI MS MS for doping control Randox assays for DoA Drugs of Abuse Array V Urine drug testing TDM of drugs for treatment of substance abuse-related disorders Drug testing to monitor treatment of drug abuse Minimum requirement for drug testing in patients Analgesic abuse ?-blockers as doping agents Detection of ß-blockers in urine Chronic alcohol abuse Cocaine CEDIA for cocaine in human serum Detection of cocaine molecules by nanoparticle-labeled aptasensors Infrared spectroscopy for detection of cocaine in saliva Marijuana Use of marijuana and synthetic cannabinoids Detection of cannabinoids ELISA for detection of synthetic cannabinoids Drug abuse for performance enhancement in sports Historical aspects of drug abuse in sports Drugs used by athletes for performance enhancement Techniques used for detection of drug abuse by athletes Mass spectrometry for detection of peptide hormones miRNAs for the detection of erythropoiesis-stimulating agents Detection of anabolic steroids Body fluids and tissues used for detection of drug abuse in sports Urine drug testing Spray (sweat) drug test kits Hair drug testing Gene doping in sports Gene transfer methods used for enhancing physical performance Misuse of cell therapy in sport Challenges of detecting genetic manipulations in athletes Drug abuse testing in race horses Limitations and future prospects Role of pharmaceutical industry in anti-doping testing 8. Markets for TDM Introduction Methods for market estimation and future forecasts Markets for TDM tests Markets for TDM and DoA testing equipment Geographical distribution of markets for TDM tests Drivers for growth of TDM markets Markets for DoA testing Unmet needs in TDM Cost-benefit studies Simplifying assays and reducing time and cost Strategies for developing markets Physician education Supporting research on TDM Biomarker patents for drug monitoring 9. Companies Profiles of companies Collaborations 10. References For more information about this report visit http://www.researchandmarkets.com/research/g4tq2x/therapeutic_drug


News Article | February 21, 2017
Site: globenewswire.com

Dublin, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Alzheimer Disease - New Drugs, Markets and Companies" to their offering. Alzheimer's disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable research is in progress to understand the pathomechanism of the disease and find a cure. The only drugs approved currently are acetylcholinesterase inhibitors but they do not correct the basic pathology of the disease, beta amyloid deposits and neurofibrillary tangles. Several new approaches emphasize neuroprotection as well. Early diagnosis of Alzheimer's disease is an important first step in management. Several biomarkers in cerebrospinal fluid, blood and urine can detect the disease. They provide a valuable aid to the clinical examination and neuropsychological testing which are the main diagnostic methods supplemented by brain imaging. Genotyping, particularly of ApoE gene alleles is also useful in the evaluation of cases and planning management. The current management of Alzheimer's disease is reviewed and it involves a multidisciplinary approach. Acetylcholinesterase inhibitors are mostly a symptomatic treatment but some claims are made about a neuroprotective effect. Currently the only approved neuroprotective therapy in is memantine. Management of these patients also require neuroleptics for aggressive behavior and antidepressants. There is an emphasis on early detection at the stage of mild cognitive impairment and early institution of neuroprotective measures. The value of mental exercise in delaying the onset of Alzheimer's disease is being recognized. Research in Alzheimer's disease still aims at elucidating the basic pathomechanisms. Animal models are important for research, particularly in testing some of the potential therapeutic approaches. There is considerable research in progress at the various centers, some of which is funded by the National Institute of Aging of the National Institutes of Health. Over 300 different compounds are at various stages of development for the treatment of Alzheimer's disease. These are classified and described. There are non-pharmacological approaches such as vagal nerve stimulation and cerebrospinal fluid shunting, which are in clinical trials. As of September 2016, the number of clinical trials of AD on US Government clinical trials web site was over 1900. Selected 231 clinical trials are listed, of which 163 are still in progress and 68 were discontinued for various reasons. Alzheimer's disease market in the seven major markets is analyzed for the year 2015. Several new therapies are expected to be in the market and the shares of various types of approaches are estimated for the future up to the year 2025. As a background to the markets, pharmacoeconomic aspects of care of Alzheimer disease patients and patterns of practice are reviewed in the seven major markets. Profiles of 144 companies involved in developing diagnostics and therapeutics for Alzheimer's disease are presented along with 93 collaborations. The bibliography contains over 910 publications that are cited in the report.The report is supplemented with 46 tables and 21 figures. Key Topics Covered: Executive Summary 1. Clinical Features, Epidemiology and Pathology 2. Diagnostic Procedures for Alzheimer Disease 3. Management of Alzheimer Disease 4. Research in Alzheimer Disease 5. Drug Discovery & Development for Alzheimer Disease 6. Markets & Finances of AD Care 7. Companies 8. References For more information about this report visit http://www.researchandmarkets.com/research/dzhp8w/alzheimer_disease


News Article | February 15, 2017
Site: www.businesswire.com

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of Jain PharmaBiotech's new report "Gene Therapy - Technologies, Markets and Companies" to their offering. Gene therapy technologies are described in detail including viral vectors, nonviral vectors and cell therapy with genetically modified vectors. Gene therapy is an excellent method of drug delivery and various routes of administration as well as targeted gene therapy are described. There is an introduction to technologies for gene suppression as well as molecular diagnostics to detect and monitor gene expression. Clinical applications of gene therapy are extensive and cover most systems and their disorders. Full chapters are devoted to genetic syndromes, cancer, cardiovascular diseases, neurological disorders and viral infections with emphasis on AIDS. Applications of gene therapy in veterinary medicine, particularly for treating cats and dogs, are included. Research and development is in progress in both the academic and the industrial sectors. The National Institutes of Health (NIH) of the US is playing an important part. As of 2015, over 2050 clinical trials have been completed, are ongoing or have been approved worldwide. A breakdown of these trials is shown according to the geographical areas and applications. The markets for gene therapy are difficult to estimate as there is only one approved gene therapy product and it is marketed in China since 2004. Gene therapy markets are estimated for the years 2016-2026. The estimates are based on epidemiology of diseases to be treated with gene therapy, the portion of those who will be eligible for these treatments, competing technologies and the technical developments anticipated in the next decades. In spite of some setbacks, the future for gene therapy is bright. The markets for DNA vaccines are calculated separately as only genetically modified vaccines and those using viral vectors are included in the gene therapy markets Profiles of 188 companies involved in developing gene therapy are presented along with 233 collaborations. There were only 44 companies involved in this area in 1995. In spite of some failures and mergers, the number of companies has increased more than 4-fold within a decade. These companies have been followed up since they were the topic of a book on gene therapy companies by the author of this report. For more information about this report visit http://www.researchandmarkets.com/research/npn4n6/gene_therapy


DUBLIN, Feb 15, 2017 /PRNewswire/ -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "RNAi - Technologies, Markets and Companies" to their offering. The markets for RNAi are difficult to define as no RNAi-based product is approved yet but...


Dublin, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Nanobiotechnology Applications, Markets and Companies" to their offering. Profiles of 251 companies, out of over 500 involved in this area, are included in the last chapter along with their 180 collaborations.The report is supplemented with 51 Tables, 31 figures and 750 references to the literature. Some of the earliest applications are in molecular diagnostics. Nanoparticles, particularly quantum dots, are playing important roles. In vitro diagnostics, does not have any of the safety concerns associated with the fate of nanoparticles introduced into the human body. Numerous nanodevices and nanosystems for sequencing single molecules of DNA are feasible. Various nanodiagnostics that have been reviewed will improve the sensitivity and extend the present limits of molecular diagnostics. An increasing use of nanobiotechnology by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology will be applied at all stages of drug development - from formulations for optimal delivery to diagnostic applications in clinical trials. Many of the assays based on nanobiotechnology will enable high-throughput screening. Some of nanostructures such as fullerenes are themselves drug candidates as they allow precise grafting of active chemical groups in three-dimensional orientations. The most important pharmaceutical applications are in drug delivery. Apart from offering a solution to solubility problems, nanobiotechnology provides and intracellular delivery possibilities. Skin penetration is improved in transdermal drug delivery. A particularly effective application is as nonviral gene therapy vectors. Nanotechnology has the potential to provide controlled release devices with autonomous operation guided by the needs. Nanomedicine is now within the realm of reality starting with nanodiagnostics and drug delivery facilitated by nanobiotechnology. Miniature devices such as nanorobots could carry out integrated diagnosis and therapy by refined and minimally invasive procedures, nanosurgery, as an alternative to crude surgery. Applications of nanobiotechnology are described according to various therapeutic systems. Nanotechnology will markedly improve the implants and tissue engineering approaches as well. Of the over 1,000 clinical trials of nanomedicines, approximately 100 are selected and tabulated in major therapeutic areas. Other applications such as for management of biological warfare injuries and poisoning are included. Contribution of nanobiotechnology to nutrition and public health such as supply of purified water are also included. Future nanobiotechnology markets are calculated on the basis of the background markets in the areas of application and the share of this market by new technologies and state of development at any given year in the future. This is based on a comprehensive and thorough review of the current status of nanobiotechnology, research work in progress and anticipated progress. There is definite indication of large growth of the market but it will be uneven and cannot be plotted as a steady growth curve. Marketing estimates are given according to areas of application, technologies and geographical distribution starting with 2015. The largest expansion is expected between the years 2020 and 2025. Key Topics Covered: Part I: Applications & Markets Executive Summary 1. Introduction 2. Nanotechnologies 3. Nanotechnologies for Basic Research Relevant to Medicine 4. Nanomolecular Diagnostics 5. Nanopharmaceuticals 6. Role of Nanotechnology in Biological Therapies 7. Nanodevices & Techniques for Clinical Applications 8. Nanooncology 9. Nanoneurology 10. Nanocardiology 11. Nanopulmonology 12. Nanoorthopedics 13. Nanoophthalmology 14. Nanomicrobiology 15. Miscellaneous Healthcare Applications of Nanobiotechnology 16. Nanobiotechnology and Personalized Medicine 17. Nanotoxicology 18. Ethical and Regulatory Aspects of Nanomedicine 19. Research and Future of Nanomedicine 20. Nanobiotechnology Markets 21. References Part II: Companies 22. Nanobiotech Companies For more information about this report visit http://www.researchandmarkets.com/research/j5c83r/nanobiotechnology


Dublin, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Biochips and Microarrays - Technologies, Markets and Companies" to their offering. This report is an analysis of biochip/microarray markets based on technologies and applications. The report starts with a description of technologies as a basis for estimation of markets. Technologies include array comparative genomic hybridization (CGH), copy number variation (CNV), DNA methylation, ChIP-Chip, RNA splice variants, and microRNA. Separate chapters are devoted to protein biochips/microarrays, microfluidics and nanobiotechnology-based nano-arrays. Various applications of biochips and microarrays are described throughout the report. Areas of application such as point-of-care, genetic screening, cancer, and diagnosis of infections are included. Separate chapters are devoted to applications in drug discovery and development as well as personalized medicine The report provides current share of each segment: market size in 2016 and projected value for the years 2021 and 2026. Gene expression has the largest share and is an established market. Share of microarray technologies in other areas will grow with the maximum growth in RNA splice variants followed by epigenetics. The growth in protein microarrays is somewhat less, partly because it is more mature than the other submarkets and has already shown considerable growth in the past. Impact of next generation sequencing on segments of microarray markets is identified. Customer requirements and unmet needs are described. Markets are also analyzed according to geographical areas. Brief profiles of companies involved in biochip/microarray technologies are provided. Currently selected 92 companies are included along with listing of 120 collaborations between companies. The text is supplemented by 21 tables, 11 figures and 140 references to literature. Key Topics Covered: Executive Summary 1. Introduction 11. References For more information about this report visit http://www.researchandmarkets.com/research/d2np4r/biochips_and Source: Jain PharmaBiotech


Dublin, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Biochips and Microarrays - Technologies, Markets and Companies" to their offering. This report is an analysis of biochip/microarray markets based on technologies and applications. The report starts with a description of technologies as a basis for estimation of markets. Technologies include array comparative genomic hybridization (CGH), copy number variation (CNV), DNA methylation, ChIP-Chip, RNA splice variants, and microRNA. Separate chapters are devoted to protein biochips/microarrays, microfluidics and nanobiotechnology-based nano-arrays. Various applications of biochips and microarrays are described throughout the report. Areas of application such as point-of-care, genetic screening, cancer, and diagnosis of infections are included. Separate chapters are devoted to applications in drug discovery and development as well as personalized medicine The report provides current share of each segment: market size in 2016 and projected value for the years 2021 and 2026. Gene expression has the largest share and is an established market. Share of microarray technologies in other areas will grow with the maximum growth in RNA splice variants followed by epigenetics. The growth in protein microarrays is somewhat less, partly because it is more mature than the other submarkets and has already shown considerable growth in the past. Impact of next generation sequencing on segments of microarray markets is identified. Customer requirements and unmet needs are described. Markets are also analyzed according to geographical areas. Brief profiles of companies involved in biochip/microarray technologies are provided. Currently selected 92 companies are included along with listing of 120 collaborations between companies. The text is supplemented by 21 tables, 11 figures and 140 references to literature. Key Topics Covered: Executive Summary 1. Introduction 11. References For more information about this report visit http://www.researchandmarkets.com/research/d2np4r/biochips_and Source: Jain PharmaBiotech


Jain K.K.,Jain PharmaBiotech
BMC Medicine | Year: 2010

Nanooncology,the application of nanobiotechnology to the management of cancer,is currently the most important chapter of nanomedicine.Nanobiotechnology has refined and extended the limits of molecular diagnosis of cancer,for example,through the use of gold nanoparticles and quantum dots. Nanobiotechnology has also improved the discovery of cancer biomarkers,one such example being the sensitive detection of multiple protein biomarkers by nanobiosensors.Magnetic nanoparticles can capture circulating tumor cells in the bloodstream followed by rapid photoacoustic detection. Nanoparticles enable targeted drug delivery in cancer that increases efficacy and decreases adverse effects through reducing the dosage of anticancer drugs administered. Nanoparticulate anticancer drugs can cross some of the biological barriers and achieve therapeutic concentrations in tumor and spare the surrounding normal tissues from toxic effects. Nanoparticle constructs facilitate the delivery of various forms of energy for noninvasive thermal destruction of surgically inaccessible malignant tumors.Nanoparticle-based optical imaging of tumors as well as contrast agents to enhance detection of tumors by magnetic resonance imaging can be combined with delivery of therapeutic agents for cancer.Monoclonal antibody nanoparticle complexes are under investigation for diagnosis as well as targeted delivery of cancer therapy.Nanoparticle-based chemotherapeutic agents are already on the market,and several are in clinical trials. Personalization of cancer therapies is based on a better understanding of the disease at the molecular level,which is facilitated by nanobiotechnology.Nanobiotechnology will facilitate the combination of diagnostics with therapeutics, which is an important feature of a personalized medicine approach to cancer. © 2010 Jain; licensee BioMed Central Ltd.


Dublin, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Nitric Oxide - Therapeutics, Markets and Companies" to their offering. This report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs are described as well as the companies involved in developing them. Nitric oxide (NO) can generate free radicals as well as scavenge them. It also functions as a signaling molecule and has an important role in the pathogenesis of several diseases. A major focus is delivery of NO by various technologies. Another approach is modulation of nitric oxide synthase (NOS), which converts L-arginine to NO. NOS can be stimulated as well as inhibited by pharmacological and gene therapy approaches. Important therapeutic areas for NO-based therapies are inflammatory disorders, cardiovascular diseases, erectile dysfunction, inflammation, pain and neuroprotection. The first therapeutic use of NO was by inhaltion for acute respiratory distress syndrome (ARDS). NO-donors, NO-mimics and NOS modulators are described and compared along with developmental status. NO-related mechanisms of action in existing drugs are identified. Various pharmacological approaches are described along with their therapeutic relevance. Various approaches are compared using SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis. NO-based therapies are compared with conventional approaches and opportunities for combination with modern biotechnology approaches are described. Share of drugs where NO is involved in the mechanism of action is analyzed in the worldwide pharmaceutical market for 2016 and is projected to 2021 and 2026 as new drugs with NO-based mechanisms are introduced into the market. Various strategies for developing such drugs are discussed. Several companies have a product or products involving NO and free radicals. The report includes profiles of 35 companies involved in this area of which 9 have a significant interest in NO-based therapeutics. Other players are pharmaceutical and biotechnology companies as well as suppliers of products for NO research. Unfulfilled needs in the development of NO-based therapeutics are identified. Important 18 collaborations in this area are tabulated. There are numerous publications relevant to NO. Selected 500 references are included in the bibliography. The text is supplemented with 26 tables and 29 figures.It is concluded that the future prospects for NO-based therapies are bright and fit in with biotechnology-based approaches to modern drug discovery and development. It is anticipated that some of these products will help in meeting the unfulfilled needs in human therapeutics. Key Topics Covered: 1. Introduction 3. Role of NO in Physiology 4. Role of NO in Diseases 10. References For more information about this report visit http://www.researchandmarkets.com/research/ddj599/nitric_oxide


News Article | February 20, 2017
Site: globenewswire.com

Dublin, Feb. 20, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Proteomics - Technologies, Markets and Companies" to their offering. This report describes and evaluates the proteomic technologies that will play an important role in drug discovery, molecular diagnostics and practice of medicine in the post-genomic era - the first decade of the 21st century. Proteomics is providing a better understanding of pathomechanisms of human diseases. Analysis of different levels of gene expression in healthy and diseased tissues by proteomic approaches is as important as the detection of mutations and polymorphisms at the genomic level and may be of more value in designing a rational therapy. Protein distribution / characterization in body tissues and fluids, in health as well as in disease, is the basis of the use of proteomic technologies for molecular diagnostics. Proteomics will play an important role in medicine of the future which will be personalized and will combine diagnostics with therapeutics. Important areas of application include cancer (oncoproteomics) and neurological disorders (neuroproteomics). The text is supplemented with 44 tables, 28 figures and over 500 selected references from the literature. The number of companies involved in proteomics has increased remarkably during the past few years. More than 300 companies have been identified to be involved in proteomics and 224 of these are profiled in the report with 456 collaborations. The markets for proteomic technologies are difficult to estimate as they are not distinct but overlap with those of genomics, gene expression, high throughput screening, drug discovery and molecular diagnostics. Markets for proteomic technologies are analyzed for the year 2016 and are projected to years 2021 and 2026. The largest expansion will be in bioinformatics and protein biochip technologies. Important areas of application are cancer and neurological disorders Key Topics Covered: Part I: Technologies & Markets Executive Summary 1. Basics of Proteomics 12. References Part II: Companies 11. Companies involved in developing proteomics For more information about this report visit http://www.researchandmarkets.com/research/n9q3zl/proteomics

Loading Jain PharmaBiotech collaborators
Loading Jain PharmaBiotech collaborators